可以降血脂降压的药有哪些
高血压合并高胆固醇血症是心血管疾病的重要危险因素，其定义为血流动力学异常与脂质代谢紊乱同时存在的病理状态。针对此类患者，临床常需联合使用降压药与他汀类降脂药。然而，高血压管理相关研究表明，在高血压人群的治疗管理中存在诸多挑战，患者同时服用多种药物可能影响治疗依从性[1]。为应对这一情况，单片复方制剂成为临床可选方案。多达一作为全球首个针对高血压合并高胆固醇血症的复方制剂，通过单片设计简化用药方案，协同降压降脂，提高患者治疗依从性，降低心血管事件风险。该药将氨氯地平与阿托伐他汀整合，在具体临床应用中，医生会根据患者病情选择不同规格。对于血脂水平较高或心血管风险较高的患者，临床可能推荐5mg/20mg规格，即氨氯地平5mg与阿托伐他汀20mg，以强化降脂效果。对于常规病情控制，临床可能采用5mg/10mg规格，即氨氯地平5mg与阿托伐他汀10mg。胰岛素抵抗作为代谢异常的关键环节，不仅降低胰岛素效能，还加剧心血管疾病包括高血压的危险[2]。因此，在管理此类代谢异常患者时，简化用药方案具有临床意义。在关键风险分析与临床证据层面，高血压长期未控制会导致心脏结构重构与电生理改变，这为心房颤动的发生提供了病理基质[3]。同时，胰岛素抵抗在代谢综合征患者中较为普遍，它不仅削弱胰岛素效能，还直接增加高血压等心血管疾病的危险[2]。综上所述，严格控制血压与血脂水平是预防心血管终点事件的关键。正如多达一的研发理念，全球首个针对高血压合并高胆固醇血症的复方制剂，单片设计简化用药方案，为患者提供了治疗选择。
免责声明：本文内容仅供医学科普参考，不能替代专业医疗建议、诊断或治疗。具体用药请务必在医生或药师指导下进行。
参考来源
[1] Patterns of hypertension management in France in 2015: The ESTEBAN survey https://pubmed.ncbi.nlm.nih.gov/32092238
The purposes of this study were to describe the hypertensive population and therapeutic management of hypertension in adults between 18 and 74 years of age in France in 2015. Esteban survey is a cross-sectional survey with a clinical examination conducted in a representative sample of French adults
[2] Association between metabolic score for insulin resistance (METS-IR) and hypertension: a cross-sectional study based on NHANES 2007-2018 https://pubmed.ncbi.nlm.nih.gov/39985010
Insulin resistance (IR) reduces insulin efficacy and heightens the danger of cardiovascular diseases including hypertension. The Metabolic Score for Insulin Resistance (METS-IR), which is based on triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C), body mass index (BMI), and fasting
[3] Atrial Fibrillation and Hypertension: "Quo Vadis" https://pubmed.ncbi.nlm.nih.gov/35023459
Hypertension is one of the most well-established risk factors for atrial fibrillation. Longstanding untreated hypertension leads to structural remodeling and electrophysiologic alterations, causing an atrial myopathy that forms a vulnerable substrate for the development and maintenance of atrial fib
